ArticleCurrent medicinal chemistry2026
Predicting Clinical Prognosis and Treatment Response in Glioblastoma Based on Gene Replication Stress-Related Features.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlioblastoma (GBM) is a frequent malignant glioma among astrocytic tumors. Traditional pathological diagnostic criteria inadequately capture the underlying biological heterogeneity, highlighting the need for novel biomarkers to improve the diagnostic and prognostic accuracy of GBM.
methodsBased on the GBM-related data from The Cancer Genome Atlas (TCGA), Replication Stress-related Genes (RSGs) were collected. The RSG feature scores were calculated by ssGSEA and combined with WGCNA to screen target module genes. Enrichment analysis of the modular signature genes was conducted using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Prognostic genes were screened by univariate Cox and multivariate Cox regression analyses to establish a prognostic model for GBM. The Tumor Microenvironment (TME) was assessed using MCPcounter and TIMER methods. Immunotherapeutic responses and drug sensitivity responses were evaluated using the TIDE method. Finally, the role of PDCL3 in GBM was explored via immunohistochemistry, qRT-PCR, wound-healing, and transwell assays.
resultsWGCNA identified RSG-associated module genes enriched in DNA replication, DNA-dependent ATPase activity, and other pathways. Four characterized genes (PDCL3, STEAP2, NXPH4, MPST) were selected to establish a Riskscore model for GBM. The risk score of the model was significantly related to the infiltration of myeloid dendritic cells, endothelial cells, and fibroblasts. The Riskscore was significantly positively correlated with the TIDE score, indicating higher immune escape potential in the high-risk group. The high-risk group was sensitive to Vinorelbine and Crizotinib. Through in vitro experiments, it was observed that knocking down PDCL3 noticeably inhibited the viability, migration, and invasion capacities of U87 cells. DISCUSSION: This study validated the correlation between Oncogene-induced Replication Stress (ORS) characteristics and the prognosis of GBM, and screened RSGs to develop a Riskscore for GBM applying multiple types of regression analyses.
conclusionWe constructed and verified a four-gene ORS-based prognosis model for GBM, linking replication stress to immune evasion and drug sensitivity for the first time. Experimental validation confirmed the pro-tumorigenic role of PDCL3, offering potential biomarkers and therapeutic targets.
Indexed as
Identifiers
41968545What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.